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ABSTRACT
W
e review three approaches to the genetic analysis
of the biology and pathobiology of human aging.
The ﬁrst and so far the best-developed is the
search for the biochemical genetic basis of varying
susceptibilities to major geriatric disorders. These include a
range of progeroid syndromes. Collectively, they tell us much
about the genetics of health span. Given that the major risk
factor for virtually all geriatric disorders is biological aging,
they may also serve as markers for the study of intrinsic
biological aging. The second approach seeks to identify allelic
contributions to exceptionally long life spans. While linkage
to a locus on Chromosome 4 has not been conﬁrmed,
association studies have revealed a number of signiﬁcant
polymorphisms that impact upon late-life diseases and life
span. The third approach remains theoretical. It would
require longitudinal studies of large numbers of middle-aged
sib-pairs who are extremely discordant or concordant for
their rates of decline in various physiological functions. We
can conclude that there are great opportunities for research
on the genetics of human aging, particularly given the huge
fund of information on human biology and pathobiology, and
the rapidly developing knowledge of the human genome.
Introduction
Other articles in PLoS Genetics and elsewhere have
documented remarkable progress in genetic aspects of aging
in model organisms. These studies have revealed what can be
regarded as the ﬁrst ‘‘public’’ mechanism of aging, that is to
say, a biochemical genetic pathway, modulation of which can
alter the life spans of diverse species [1–3]. We applaud the
remarkable achievements of our colleagues working with these
models. One of us was in fact an early champion of this
approach [4]. These model systems have several limitations,
however. First, the life spans of these models are dramatically
shorter than those of humans. The mutations that extend life
span result in increases of a few weeks or months in
invertebrates and a year or so in rodents. These species are ‘‘r’’
selected species, characterized, in part, by rapid rates of
development, high degrees of fecundity, and short life spans
[5]. Human beings are ‘‘K’’ selected organisms, characterized,
in part, by long periods of development, comparatively few
progeny and long life spans [5]. It is therefore possible that the
biochemical genetic results from model organisms may not be
relevant for humans, whose life history strategies are quite
different. It should be noted, for example, that a polymorphic
locus (CETP) that modulates susceptibility to several major
diseases of aging does not exist in invertebrates or rodents.
Second, while we have learned a great deal about
developmental biology from worms, ﬂies, and mice, there is a
paucity of detailed information on the pathophysiology of
aging and of their variations among genetically heterogeneous
wild-type populations, particularly in worms and ﬂies. In
contrast, there is a vast literature on these and all other aspects
of human biology, including remarkable progress in human
genetics (Table 1). Moreover, physicians have provided
detailed characterizations of late-life disabilities and diseases
in human populations (Table 2). Third, additional and unique
DNA sequences have evolved in Homo sapiens, including rapidly
evolving functionally signiﬁcant intronic sequences that
distinguish us from our nearest relative, the common
chimpanzee (Pan troglodytes), whose life span is approximately
half that of humans) [6,7] (see, however, evidence of a single
outlier who lived to age 74, http://genomics.senescence.info/
species/biblio.php?id¼0505). Fourth, most gerontological
investigations of model organisms have utilized highly inbred
organisms typically examined in a single environment. By
contrast, human geneticists, particularly medical geneticists,
see the results of a huge range of gene–gene and gene–
environmental interactions. They therefore have considerable
opportunities to contribute to our understanding of why
individual patterns of aging exhibit such substantial
variations. Some of this understanding should prove to be
unique to our species, as they will include ‘‘private’’
biochemical genetic mechanisms—that is to say, mechanisms
that are characteristic of only particular subsets of individuals
[1–3]. These different patterns of aging certainly include
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late-life diseases and disabilities. As we shall see below, these
are all part of a spectrum of phenotypes that escape the force
of natural selection and are thus, in our view, part and parcel
of complex aging processes. We can refer to them generically
as ‘‘senescent phenotypes’’ [8]. Moreover, given the likelihood
that intrinsic physiological declines in structure and function
are early precursors of such geriatric disorders, investigators
have the opportunity to work backwards from the disease to
elucidate underlying mechanisms of aging, mechanisms that
set the stage for the emergence of these clinically important
disorders. Finally, studies of genetic contributions to late-life
disorders can elucidate variations in health span, which can be
deﬁned as the period of life during which an individual is free
of chronic illness and substantial functional decrements.
Genetic and epigenetic factors that limit health span are
certainly legitimate aspects of biogerontological research,
particularly from the point of view of medical economics. A
cogent example of why long life span cannot be equated with
long health span comes from studies of pedigrees with certain
forms of autosomal dominantly inherited frontotemporal
dementia. Affected subjects may exhibit up to a 26-year
history of personality disorders, cognitive decline and,
eventually, overt dementia [9]. The underlying mutation in
these particular pedigrees involves mutations at the tau locus,
leading to a greatly accelerated rate of accumulation of
neuroﬁbrillary tangles, lesions that are commonly observed, in
much smaller numbers, in the brains of much older individuals
with wild-type versions of that gene. (Studies of different
pedigrees with frontotemporal dementia have recently
documented causal mutations at a second locus, progranulin
[PRGN], the product of which is a glycoprotein that probably
functions as a secreted growth factor [10]). We shall give below
only a few other examples of how disorders listed in Table 2
have led to molecular understanding of certain common
forms of pathophysiology in aging human subjects, thus
explaining some of the variations in senescent phenotypes.
Human geneticists have only recently begun to use the
tools of linkage analysis and association studies to identify
alleles contributing to exceptionally long life spans.
Interesting candidates have emerged from these studies.
There is virtually no information, however, on the genetic
basis of differential rates of decline in well-deﬁned
physiological functions among human populations. We shall
argue that such studies, particularly those that are initiated in
middle age, before the onset of complicating comorbidities,
should have a high priority for research, as they would have
the potential to discover genes that impact on rates of aging
within various organ systems. Such investigations, moreover,
would serve as tests of the null hypothesis that there is
signiﬁcant asynchrony in rates of physiological aging among
major body systems in human subjects. Selective pressures
can be expected to maintain a degree of synchrony in the
rates at which various organ functions decline [11,12], but
that synchrony is not exceptionally tight, as is evident from
clinical observations of marked variations in patterns of
senescence. The pursuit of such investigations in human
populations has numerous advantages, not the least of which
is that they are so relevant to the human condition,
particularly with regard to higher cognitive functions.
An Evolutionary Biological Approach to
Understanding Gene Action in Human Aging
The classical evolutionary biological theory of aging tells us
that senescence occurs in age-structured populations because
of the decline in the force of natural selection with age [11–
13]. That generalization has been challenged recently [14].
Certain species of ﬁsh, for example, continue to grow
throughout their life spans; for such species, rates of aging
may be ‘‘negligible’’ [15,16] and the force of natural selection
could conceivably increase with age [17]. No human being has
ever exhibited such a life history, however. All physiological
studies have conﬁrmed gradual functional declines in
multiple body systems beginning at middle age, even for
cohorts of exceptional athletes [18]. A wide variety of diseases
and disabilities accompany these physiological declines.
It is not generally appreciated that the evolutionary theory
of why we age provides clues to how we age [19–21]. Classes of
such gene actions include: (1) ‘‘longevity assurance,’’ genes
that enhance structure and function of the organism
throughout the life span; (2) ‘‘antagonistic pleiotropy,’’ alleles
selected because of enhanced reproductive ﬁtness early in the
life span, but with negative effects late in the life span, when
those effects will have escaped the force of natural selection;
and (3) ‘‘mutation accumulation,’’ constitutional mutations
that do not reach a level of phenotypic expression until late
in the life span—once again, when they will have escaped the
force of natural selection, and thus could not be purged from
the population. The evolutionary biological theory of aging
predicts a polygenic basis for the control of rates of aging.
While single gene variations can indeed enhance the life
spans of model organisms, these involve the tweaking of
diapauses [22,23], biochemical genetic pathways that most
certainly did not escape the force of natural selection, as they
were designed to enhance reproductive ﬁtness by down-
regulating reproductive activity and protecting the soma
during transient environmental challenges. As such, they will
eventually be trumped by a variety of gene actions that are
predicted by the evolutionary biological theory of aging [21].
As discussed below, evolutionary ideas can also be borrowed
and applied to one or two overlapping generations as an aid
to the discovery of genotypes modulating longevity and age-
related diseases.
Table 1. Some Reasons Why Homo sapiens Will Become THE
model Organism of the 21st Century: PubMed Citations from
1950 to May 2006
Discipline C. elegans D. melanogaster H. sapiens
Anatomy 3,275 7,814 1,644,813
Physiology 10,165 22,511 3,624,921
Biochemistry 537 1,147 157,250
Genetics 7,998 18,798 825,834
Developmental biology 61 98 1,359
Microbiology 149 313 317,993
Pathology 295 356 1,138,227
Pharmacology 1,698 3,964 2,080,405
Behavior 581 1,721 655,900
Ecology 12 51 6,913
doi:10.1371/journal.pgen.0030125.t001
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Modulating Susceptibility to Late-Life Disorders
Table 2 lists 87 disease and disability phenotypes that
commonly emerge in geriatric subjects. These result in a
substantial proportion of the overall morbidity and mortality
in the developed societies and are responsible for a major
proportion of the huge costs of Medicare in the United
States. These costs are likely to increase substantially, given
demographic trends [24]. A very large number of genetic
variants that advance the ages of onset and/or the rates of
progression of these phenotypes can be found by online
searches of Online Mendelian Inheritance in Man (http://
www.ncbi.nlm.nih.gov/sites/entrez?db¼OMIM). These have the
potential to reveal pathogenetic mechanisms. They can be
divided into two major categories. One subset consists of
mutations that impact upon a number of such phenotypes;
they have been referred to as ‘‘segmental progeroid
syndromes’’ [25]. A second group consists of allelic variants
that impact predominantly on only a single tissue or organ
system; these have been referred to as ‘‘unimodal progeroid
syndromes’’ [26]. We should be alert, however, to the
possibility that putative unimodal syndromes may in fact have
more widespread, systemic effects; a striking example has
been uncovered for the case of a mouse model of Huntington
disease, in which a metabolic abnormality of brown fat and a
defective regulation of body temperature were found to be
associated with the triplet repeat sequences previously
though to have an exclusive impact upon the central nervous
system [27]. Striking examples of segmental and unimodal
progeroid syndromes have been recently reviewed [8,28];
these have indeed provided important insights into
mechanisms of aging—for example, the role of genomic
instability for the case of many segmental disorders and the
role of abnormal protein aggregates for the case of various
unimodal dementing disorders. No single locus has ever been
discovered, however, that appears to accelerate the rates of
onset and/or the rates of progression of all senescent
phenotypes [25]. Patients with Werner syndrome (WS), caused
by mutation at a member (WRN) of the RecQ family of
helicases [29], exhibit accelerating rates of development of all
forms of arteriosclerosis, type 2 diabetes mellitus, gonadal
atrophy, skin atrophy, hair loss and hair greying, regional loss
of subcutaneous tissue, osteoporosis, ocular cataracts, and
neoplasia [25]. While deserving of greater study, there is so far
no convincing evidence of an acceleration in the rates of
development of synaptic loss, beta amyloidosis of blood
vessels or parenchyma, granulovacuolar degenerations, or
neuroﬁbrillary lesions [30], markers that accumulate, to
varying degrees, in the aging brains of many aging human
subjects, with or without a clinical or neuropathological
diagnosis of Alzheimer disease. Those lesions are very
abundant in that disorder, which exhibits exponential
increases after the age of 65, with prevalence rates 25%–48%
for persons over age 85 [31]. There are additional interesting
discordances between the phenotype of WS subjects and what
is commonly found in ‘‘usual’’ or ‘‘normative’’ aging. For
example, the osteoporosis of WS is disproportionately severe
in the bones of the lower limbs rather than in the vertebral
bodies [25] and the patterns of neoplasia are quite unusual, as
WS patients exhibit a high prevalence of sarcomas and rare
neoplasms [32]. These are among the reasons for referring to
such syndromes as ‘‘progeroid’’ (‘‘like’’ premature aging). On
the other hand, as noted above, the biochemical genetic
ﬁndings are consistent with a growing body of evidence
implicating genomic instability as a common basic
mechanism of aging [33,34]. Somatic cells from subjects with
WS exhibit marked accelerations in the rates of replicative
senescence of several somatic cell types [35]. The discovery
that G quartet motifs at telomeres are among the favored
substrates for the WRN locus [36,37] is consistent with the
important role of telomere loss as a mechanism leading to the
replicative senescence of somatic cells [38]. WS has also
pointed to the importance of aberrations in DNA
transactions within the lens epithelial cells as an important
mechanism of cataractogenesis, as opposed to post-
translational alterations of lens crystallins, an alternative
pathogenetic mechanism [39]. Patients with WS and the
Hutchinson-Gilford Progeria Syndrome (HGPS), as well as a
number of other progeroid syndromes, exhibit an accelerated
loss of somatic cells, consistent with the widespread atrophy
one observes in senescent human subjects. Finally, an
important argument for a commonality of mechanisms of
aging in HGPS and usual aging is that the splice variant
caused by the common HGPS mutation, which functions as a
dominant negative, thus impairing lamin A structure and
function [40], also appears in the aging tissues of normal
humans [41]. This may explain the appearance of comparable
nuclear morphological abnormalities in the aging somatic
cells of normal individuals, albeit at lower frequencies than
that observed in the cells of HGPS patients [41].
A recent example of encouraging progress in the discovery
of unimodal progeroid syndromes was the discovery of two
polymorphic loci, complement factor H and a predicted gene
on Chromosome 10q, LOC387715, that modulate
susceptibility to age-related macular degeneration [42–44]. A
prospective study of US nurses and health professionals has
revealed a ;50-fold increase (95% CI: 10.8–237) in the risk of
age-related macular degeneration for subjects who are
homozogous for both risk alleles [45]. Smoking and obesity
increased the risks associated with these variants [45]. Of
interest is the lack of evidence for an association with
complement factor H in a Japanese population [46], but the
presence of an association in this population with the
polymorphism at the 10q locus [47]. Enormous efforts have
also been directed to families with both early- and late-onset
dementias of the Alzheimer type. All three autosomal
dominant genes responsible for the comparatively early-onset
variety impact upon the processing of the beta amyloid
precursor protein, the result being increased proportions of
the highly amyloidogenic amyloid beta 1–42 peptide (for a
brief and selective review of this huge literature, see [48].
These ﬁndings are consistent with a major etiological role of
amyloid beta peptides in the vastly more common late onset
cases, where the neuropathological diagnosis is made on the
basis of amyloid plaques and neuroﬁbrillary tangles. With the
exception of the important risk factor of the epsilon 4 allele
at the APOE locus (reviewed by [49]), numerous candidate loci
remain to be fully validated as contributors to the much more
common late onset forms of late-life dementia. For a
comprehensive list of these candidate loci and their
polymorphic alleles, see http://www.alzforum.org/res/com/gen/
alzgene/default.asp.
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Human Longevities
Centenarians have outlived any exceptionally long-lived
invertebrate model by ;100 years and any comparable
rodent model by ;30-fold. Human subjects in general and
centenarians in particular outlive their nearest relatives, the
common chimpanzee, by many decades [50]. This happy state
of affairs is clearly the result of evolutionary changes in our
constitutional genomes [51]. Since the structure of our
proteins and those of chimpanzees is very nearly identical
[52], our enhanced life spans are probably related primarily
to regulatory RNA species, an area of scholarship that has just
begun [6,7] and has not yet been applied to the study of the
evolution of varying longevities.
Our task here, however, is to review progress towards the
elucidation of genetic factors that contribute to exceptional
longevities of individual members of Homo sapiens. The life
expectancies of centenarians at birth are nearly double that
of most members of their birth cohort and, on average, have
surpassed current life expectancy by 22 years. Environmental
and stochastic contributions to human life span likely play
important roles in the determination of such exceptionally
long survivals, as inferred from the twin studies discussed
below. Familial aggregates of exceptional longevity do not
rule out major environmental factors that are the result of
cultural inheritance (e.g., lifestyles, nutrition); such factors
could explain, in part, why the progeny of long-lived
members of the Framingham study exhibit advantageous
cardiovascular risk proﬁles in middle age [53]. Nevertheless,
evidence consistent with a signiﬁcant heritable component of
exceptional longevity is impressive. Parents of centenarians
(born in ;1870) were shown to have approximately nine
times the odds of living to the tenth decade as compared to
controls [54]. Siblings of centenarians were shown to have up
to an ;18-fold increase in the chance of achieving a similar
age [55]. Such data have raised the possibility that some
speciﬁc genetic modulators of aging in humans can be
identiﬁed using such populations, and that conserved
pathways for exceptional longevity might thus be validated.
Exceptional longevity is obviously coupled with exceptional
resistance to diseases that lead to earlier mortalities. We do
not have the required biomarkers, however, to clearly
disentangle the two phenomena. The research suggested in
the last section of this essay may eventually lead to such
markers, however.
During the last decade, centenarian populations (New
England American, Mormon, Ashkenazi Jewish, Islandic,
Okinawan, Japanese, Italian, Irish, and Dutch, among others
[54,56–60] have been used for association studies to search for
candidate longevity genes or pathways. Particularly striking
examples have included PON1 [61–67] IGF-1 [68–71], PAPR-1
[72,73], cytokines, enzymatic antioxidants such as superoxide
dismutases [74,75], and elements of lipid metabolism [76,77].
Some signiﬁcant differences have been noted between
younger cohorts and centenarians in the prevalence of
speciﬁc genotypes and sometimes in their associated protein
activities. These interesting observations, however, have
suffered and will continue to suffer from several limitations.
In addition to the usual problems and pitfalls of association
studies, particularly as we enter the new age of whole genome
scans [78], there is the special problem of the identiﬁcation of
appropriate controls for a cohort of exceptionally long-lived
individuals. One innovative approach has been an
experimental design based upon a genetic analysis of the
progeny of centenarians, giving the opportunity for matched
spousal controls [79].
The New England Centenarian Study recruited long-lived
sib-ships for a genome-wide scan of linkage to exceptional
longevity. A region on Chromosome 4 was implicated [80]. By
high density SNP analysis an exonic genotype in microsomal
transfer protein was thought to be the locus associated with
the exceptional longevity [81]. The original ﬁnding could not
be replicated in independent populations [82]. Such
validation is crucial because of the considerable rates of false
positives. While it is possible that the role for this gene in
longevity may only be signiﬁcant in certain populations, the
most likely explanation for the original linkage was
population stratiﬁcation. The ethnic mix within the long-
lived and younger control populations was likely to have
differed [83]. Nevertheless, it would be helpful to evaluate
other allelic variants in the same gene or in other related
genes. In any case, this early study emphasizes the need to
establish additional phenotypes associated with the
polymorphism. Although microsomal transfer protein cannot
be directly measured, evidence for a role in lipoprotein
characteristics or a relationship to age-related diseases would
have been helpful in support of a protective role. The
population stratiﬁcation problem can be ameliorated by the
selection of better-deﬁned populations, as was done for the
case of the Dutch study cited above [83].
Studies performed at the Albert Einstein College of
Medicine were based upon populations of Ashkenazi Jews and
the following considerations [84]. First, exceptional longevity
is obviously a rare phenotype (;1/10,000 individuals live to
the age of 94–110). Second, it is also apparent that, for any
given cohort, genotypes associated with comparatively early
mortality are ‘‘weeded out,’’ while a subset of genotypes are
associated with survival. Given large cohorts representing
each decade of the life span, one can examine whether those
who continue to survive exhibit biologically distinctive
phenotypes and genotypes as compared to those of younger
cohorts. Thus, the relative prevalence of favorable
‘‘longevity’’ genotypes within the population can be expected
to rise monotonically rather than abruptly or intermittently
over the life course. Because the genotypes of survivors are
‘‘selected,’’ the greater the attribution of a genotype to
longevity, the greater is the divergence from Hardy–
Weinberg equilibrium among the elderly. Using this strategy,
the Einstein group recruited signiﬁcant numbers of
Ashkenazi Jews of all ages, including ;400 individuals
between ages 95–110. Signiﬁcant increases within aging
cohorts were observed for three genotypes from among
hundreds of candidate genotypes (selected because of their
relevance for lipoprotein phenotypes) that were tested in
unrelated populations consisting of individuals between ages
50–110 years (Figure 1) [79,85]. These genotypes were: (1) the
CETP gene codon 405 isoleucine to valine variant (CETP VV);
(2) the apolipoprotein C-3 (APOC-3) gene codon A ( 641) C
variant (APOC-3 CC); and (3) a deletion at þ2019 in the
adiponectin (ADIPOQ) gene. The enrichment of the CETP
genotype is supported by evidence from two independent
populations [77,86].
While a signiﬁcant overrepresentation of a single genotype
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a candidate gene, several other criteria should be fulﬁlled
before considering it to be an important longevity assurance
gene (Figure 2).
The ﬁrst step by which the functionality of the genotype
can be studied is by determining the serum and plasma levels
of the coded protein, if it is secreted and circulating. For
example, for each of the genotypes in Figure 1 (CETP, APOC3,
and ADIPOQ), appropriate alterations in plasma levels have
been demonstrated [76,85–89]. Detailed information on the
approach to the choice of controls typically used for these
studies is given in [87]. They included spouses or other
nonrelated age-matched pairs for the progeny of
centenarians. The genomes of the latter can be expected to be
enriched with alleles for unusual longevity. Indeed, these
offspring were shown to be healthier than age-matched
controls and had more favorable lipid proﬁles.
A second step in establishing functionality is the
identiﬁcation of an intermediate phenotype. For example,
alleles at CETP and APOC3 differentially modulate
lipoprotein characteristics. These effects may vary with age
and should therefore be examined in cohorts of varying ages.
The functional value of a genotype can also be assessed
directly by functional studies of the mutant in a cellular
system in vitro. Such studies may underestimate or
overestimate the real physiological importance of the
relevant gene action in vivo, however. If the gene encodes a
protease, then studies of its speciﬁcity, tissue distribution,
and regulation are called for. If the gene encodes a cell-
surface receptor, then studies of the biochemistry of the
receptor should be done. For example, the Einstein group
recently identiﬁed novel mutations in the IGF-1 receptor of
three centenarians. AKT phosphorylation was assessed in
lymphoblastoid cell lines from these subjects and controls,
both basal and induced levels (stimulating with IGF-1). A
marked decrease in phosphorylation was observed in cells
from the centenarians with the mutant IGF-1 receptors
[89,90].
As noted in the Introduction, the enhancement of life
spans in model organisms via single gene mutations raises the
question of whether allelic variations at this pathway in
human subjects might impact intrinsic biological aging within
all tissues and thus lead to substantial increases in life span.
Among the many billions of human beings who have lived
since the time of recorded history, it is unlikely that a
spontaneous mutant of this type, say leading to a doubling of
the usual human life span, would have been missed. One
could not rule out gene actions of this type, however, that
contribute to the generation of rare, relatively healthy
centenarians. This possibility is supported by at least three
lines of evidence. First, as in the case of CETP VV, the
protection provided by certain genotypes can extend beyond
a known role in a disease entity associated with its
ascertainment (in this example, cardiovascular disease). The
CETP VV genotype is also associated with enhanced insulin
sensitivity and lower risk for hypertension, the metabolic
syndrome, and diabetes [87]. Moreover, the CETP VV
genotype protects against age-related cognitive decline and
Alzheimer’s disease [91], although the role of particular
haplotypes at that region may interact with polymorphic
alleles at the APOE locus [92].
A second example is a 2.5-fold increase, among
centenarians, in the prevalence of an apoC III promoter
variant. This variant is associated with signiﬁcant declines in
plasma levels of apoC III and a phenotype of large
doi:10.1371/journal.pgen.0030125.g001
Figure 1. Visual Presentation of the Frequency Trends of Favorable
Genotypes with Exceptional Longevity
This trend was obtained in ;400 Ashkenazi Jewish subjects over age 95
and ;600 subjects between ages 60–95 [76,87]. While these genotypes
were assessed cross-sectionally in groups between ages ;60–110, it is
important to realize that marked selection occurs during the life course.
One also should be aware of the fact that very few subjects achieve
centenarian status. Of many polymorphic candidate loci, only subjects
homozygous for CETP VV, APOC-3 CC, and ADIPOQ del/del genotypes
are markedly and significantly enriched among centenarians (see details
in text). To be considered a favorable longevity genotype, a monotonic
increase should be observed among age groups. This criterion helps to
exclude false-positive associations that occur only in one age group but
that do not exhibit trends among sequential age groups. Genotypes with
unchanged frequencies among age groups serve as partial controls for
genotypic distribution and stratification tests. The analysis of such
patterns is useful for the identification of candidate ‘‘longevity genes.’’
doi:10.1371/journal.pgen.0030125.g002
Figure 2. The Stages Needed in Order to Support the Association of a
Genotype with Longevity
While Figure 1 demonstrates how to obtain genotypes in genes that are
important for the assurance of longevity, the verification of such
genotypes requires additional analyses. First, one should seek evidence
of a relevant biological phenotype. These may include in vitro and in vivo
functional assays that demonstrate appropriate alterations in genes and
the determination of plasma or tissue levels of substances that reflect an
intermediate phenotype. Second, one should ideally develop lines of
evidence demonstrating that a given genotype is protective against
common diseases of aging, i.e., that the genotypes also modulate health
span. These various steps should help to establish genetic factors
contributing to exceptional longevity. As such, they should serve as
major clues to the pathogenesis of common diseases of aging, thus
providing rational strategies of prevention (see text).
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hypertension among subjects homozygous for this variant.
The most striking data, however, were obtained from a
retrospective study of a cohort of subjects bearing this
variant. They live signiﬁcantly longer; in fact, subjects ,95
years old with this genotype lived on average over four years
longer than those who were not homozygous for the variant.
This is indeed a very large impact upon life span when one
considers the conclusions of demographers, who have noted
that the elimination of ischemic heart disease, a disorder that
was responsible for 25.73% of all deaths in 1985, would
increase life expectancy at birth by only 3.0 years for females
and 3.55 years for males [93].
A third argument suggesting that some longevity genes are
not merely disease speciﬁc is the marked conservation of
some of these loci. For example, apoC III is under the control
of FOXO-1, a transcription factor homologous to the DAF16
gene of Caenorhabditis elegans. DAF16 is a key regulator of a
downstream suite of genes that are thought to protect the
organism from macromolecular damage and thus enhance
life span [94]. Some centenarians have novel functional
mutations in the IGF-1 receptor, as noted above. There is
evidence that the homologue in mice regulates life span and
resistance to oxidative stress [95]. Thus, while the impact of
variants at the CETP locus upon age-related diseases and
longevity may be a special feature of the biology of humans,
there is also evidence that the fruits of research on the
genetic modulation of the life spans of worms, ﬂies, and mice
may in fact be applicable to our species.
Some favorable ‘‘longevity genotypes’’ may act to buffer the
deleterious effects of genes that lead to age-related diseases.
As a result, the frequencies of deleterious genotypes may,
paradoxically, be increased among individuals with extreme
life spans. This may explain why the cholesteryl ester transfer
protein (CETP-VV) genotype appears to exhibit an additional
advantageous effect—the neutralization of the deleterious
effects of the lipoprotein(a) (Lp(a)) gene [84]. Such buffering
effects cannot be ascribed to genetic linkage. For the example
just cited, those loci are in fact on separate chromosomes.
More generally, however, it is clear that one can deﬁne two
distinct populations, each bearing the disease susceptibility
allele in question, but only one of which exhibits the putative
buffering effect.
The Role of Stochastic Events in the Modulations of
Health Span and Life Span
A study of uncensored pairs of Danish human twins has
indicated that only about one quarter of the heritability of
life span can be attributed to the constitutional genotype [96].
There are indications from twin studies of very old
individuals, however, that more robust genetic contributions
to superior health and superior cognitive functioning can be
identiﬁed [97,98]. In any case, it is quite clear that there are
substantial impacts of both environmental and stochastic
inﬂuences upon both life span and health span [99].
Discussion of environmental factors is beyond the scope of
this minireview. Sufﬁce it to say that there are likely to be a
host of ‘‘gerontogens’’ [100] with the potential to modulate
segmental and unimodal aspects of the pathobiology of aging.
Cigarette smoking is a prime example [101]. With regard to
stochastic factors, we must look to the work of colleagues who
have demonstrated, in numerous publications over many
decades, remarkable variations in life spans among highly
inbred worms, ﬂies, mice, hamsters, and rats, despite every
effort to control the environments in which such organisms
are aged. The most cogent example involved studies of C.
elegans grown in liquid cultures with axenic medium [102].
One can imagine several distinct types of stochastic events to
explain such observations. First, one can imagine stochastic
variations in the epigenetic control of gene expression. Such
a mechanism might explain, in part, recent experiments
demonstrating correlations of the expression of a transgene
for an inducible heat shock promoter/reporter with the
longevity of cohorts of C. elegans [103]. There is also evidence
of substantial ‘‘epigenetic drift’’ of gene expression within
aging pairs of human identical twins [104,105]. The sirtuin
family of histone deacetylases represents a potential causal
link between epigenetic regulation, caloric restriction, and
longevity in a number of organisms, including fruit ﬂies [106];
moreover, inactivation of a member of the sirtuin family in
mice causes phenotypes consistent with premature aging
[107]. A second obvious candidate is somatic mutation, within
both the nuclear [108] and mitochondrial [109] genomes. The
latter is a particularly attractive idea, as the stochastic events
could involve both the timing and speciﬁcity of the mutations
and the events leading from the heteroplasmic to the
homoplastic state. In that respect, certain classes of
mitochondrial rearrangements leading to multiple
replication origins might be more likely to evolve towards a
homoplastic state [110]. In contrast to point mutations, which
appear not to be major contributors to senescence [111], such
rearranged mitochondrial DNA molecules might enjoy a
selective replicative advantage over wild-type mitochondrial
DNA. A third possibility could be related to what has been
referred to in the microbial literature as ‘‘noise’’—random
ﬂuctuations in gene expression; see, for example, [112].
Whatever the mechanism, these stochastic events, and the
heritability studies mentioned above, diminish the power of
genetic analysis to discover loci at which allelic variation
modulates health span and life span. We already know a great
deal about how the constitutional genome modulates the
initiation and accumulation of somatic mutations,
particularly nuclear mutations [34], but we know very little
about how DNA sequences might set the stage for differing
degrees of epigenetic variation and transcriptional or post-
transcriptional noise.
Opportunities for Discovering Genetic
Contributions to Differential Rates of Physiological
Declines in Middle-Aged Subjects
Human geneticists, most of whom are practicing medical
geneticists, suffer from a biased ascertainment of their
subjects. With the notable exception of studies of
nonogenarians and centenarians discussed above, their
subjects present themselves because of dysfunctions and
never because of remarkably robust function. Centenarians,
however, often have a variety of comorbidities. Moreover,
given their extreme old age, it is not feasible to carry out
longitudinal studies of the rates of change of speciﬁc
physiological functions. An argument has been developed for
a different approach to the discovery of allelic variants that
are associated with unusual degrees of maintenance of
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experimental design included a focus upon subjects in their
early middle age, when early functional declines unfold, as
predicted by the evolutionary biological theory of aging. Such
subjects are typically free of comorbidities. In contrast to
centenarians, there are vast numbers of such individuals and
they are typically more compliant. They can be followed
longitudinally for many years. Moreover, they are members of
nuclear families, permitting sib-pair analysis and the use of
multiple generations for the establishment of phase
relationships of genetic markers. For many populations, there
is a rich association of relevant clinical and pedigree
information. Given sufﬁciently large cohorts of such
individuals, one has the potential to detect individuals who
are at the extreme ends of a statistical distribution of assays
for a range of physiological functions. Those physiological
assays must be highly sensitive, in order to identify
individuals at the statistical extreme of exceptionally superior
functioning. The assays should measure very speciﬁc
physiological functions, functions that are not likely to be
under highly polygenic controls. Ideally, they should also be
relatively noninvasive, relatively inexpensive, relatively rapid,
and not subject to major motivational inﬂuences that could
impact peak performance. Multiple body systems should be
interrogated, since an important null hypothesis to be tested,
as noted in our Introduction, is the lack of tight coupling of
rates of functional change among the various body systems.
Given the availability of such assays, one would be in a
position to carry out a genetic analysis on sib-pairs, starting
with index cases from the extreme tails of the distributions.
As argued by Risch and Zhang, the statistical power of such
sib-pair studies would be enhanced by the selection of sibs
showing extreme discordances [114]. The rapid technical
advances that are being made in whole genome scans (see,
e.g., http://www.perlegen.com/index.htm?whatweoffer/
why_whole_genome.html) and statistical methodologies
[115] should greatly facilitate the genetic analysis of
exceptionally slow rates of human aging in various organ
systems. “
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